Orthocell has today announced the achievement of first sales of Remplir™ in Singapore, marking another significant milestone in its global commercialisation strategy.
This rapid commercialisation, from October 2024 regulatory approval to December 2024 first sales, demonstrates both the quality of the product, and the strength of Orthocell’s partnership with Device Technologies Asia (DVT). Singapore represents a strategic gateway to the broader ASEAN market, in a global nerve repair market estimated to exceed US$3.5 billion.
DVT Asia is well placed to gain sales traction in this strategic jurisdiction, having already established relationships with target customers including leading plastic reconstructive and orthopaedic surgeons at high quality surgical centres.
Orthocell Managing Director, Paul Anderson, said:
“We are delighted to report first sales to DVT Asia earlier than expected. Device Technologies is our chosen distribution partner in Australia, New Zealand and Singapore and have moved quickly to begin selling our leading nerve repair product Remplir in Singapore. We expect additional sales, revenue growth and surgeon adoption of Remplir to accelerate in the new year.”